EP0180413B1 - Anticorps monoclonal contre le cancer humain - Google Patents

Anticorps monoclonal contre le cancer humain Download PDF

Info

Publication number
EP0180413B1
EP0180413B1 EP85307678A EP85307678A EP0180413B1 EP 0180413 B1 EP0180413 B1 EP 0180413B1 EP 85307678 A EP85307678 A EP 85307678A EP 85307678 A EP85307678 A EP 85307678A EP 0180413 B1 EP0180413 B1 EP 0180413B1
Authority
EP
European Patent Office
Prior art keywords
cells
monoclonal antibody
hybridoma
cancer
monoclonal antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP85307678A
Other languages
German (de)
English (en)
Other versions
EP0180413A2 (fr
EP0180413A3 (en
Inventor
Eiichi Tahara
Atsushi Ochiai
Hiroshi Yokozaki
Toyoharu Wakunaga Seiyaku K. K. Hozumi
Eikai Wakunaga Seiyaku K. K. Kyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wakunaga Pharmaceutical Co Ltd
Original Assignee
Wakunaga Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP22383084A external-priority patent/JPS61103837A/ja
Priority claimed from JP60198592A external-priority patent/JPS61104783A/ja
Application filed by Wakunaga Pharmaceutical Co Ltd filed Critical Wakunaga Pharmaceutical Co Ltd
Publication of EP0180413A2 publication Critical patent/EP0180413A2/fr
Publication of EP0180413A3 publication Critical patent/EP0180413A3/en
Application granted granted Critical
Publication of EP0180413B1 publication Critical patent/EP0180413B1/fr
Expired legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal

Definitions

  • the present invention relates to monoclonal antibodies capable of reacting with cancer cells from more than one human organ but substantially not reacting with normal cells, a process for production of the monoclonal antibodies, hybridoma cell lines producing the monoclonal antibodies, and a process for production of the cell lines.
  • the monoclonal antibody To use a monoclonal antibody for the diagnosis of cancer, the monoclonal antibody must react with or bind to the cancer cells but should not react with or bind to normal cells. In some cases, it is desirable that the monoclonal antibody react with or bind to cancer cells from more than one human organ, so that more than one kind of cancer cell can be simultaneously detected.
  • Japanese Unexamined Patent Publication No. 59-128397 discloses a monoclonal antibody against human stomach cancer, which reacts with well-differentiated stomach cancer cells but which has only a weak reaction with poorly-differentiated stomach cancer cells. This publication does not disclose whether the monoclonal antibody reacts with normal cells.
  • TMK-l cells i.e., cells derived from human stomach poorly-differentiated adenocarcinoma cells and transplanted to SC-6-JCK nude mice, as an antigen.
  • an object of the present invention is to provide a monoclonal antibody against human cancer, characterized in that the monoclonal antibody is produced by a hybridoma cell line obtained from the fusion of B-lymphocyte immunized with cells of human cancer origin and tumor cells, and reactive with cancer cells from more than one human organ but substantially not reactive with normal cells.
  • Another object of the present invention is to provide a process for production of the above-mentioned monoclonal antibody, wherein the above-mentioned hybridoma cells are cultured in a culture medium in vitro or in the body of an animal in which the hybridoma cells can grow, and the monoclonal antibody is recovered from the cultured medium or ascites taken from the animal and optionally purified by a conventional process.
  • Another object of the present invention is to provide a hybridoma cell line obtained by the fusion of B-lymphocyte immunized with cells of human cancer origin and tumor cells, and capable of producing a monoclonal antibody against human cancer, which monoclonal antibody is reactive with cancer cells from more than one human organ but substantially not reactive with normal cells.
  • Another object of the present invention is to provide a process for production of the above-mentioned hybridoma cell line, comprising preparing B-lymphocytes immunized with cells of human cancer origin, fusing the B-lymphocyte with tumor cells, and cloning and selecting hybridoma producing a desired monoclonal antibody.
  • the present invention provides a hybridoma cell line capable of producing a monoclonal antibody against human cancer, which hybridoma is selected from the group consisting of IFO-50061 and IFO-50062. Also provided are: monoclonal antibodies against human cancers produced by said hybridomas; methods for producing a monoclonal antibody as defined above by culturing the hybridomas in an in vitro or in vivo system, recovering the antibody from culture medium or ascites as appropriate and optionally purifying the antibody; and pharmaceutical preparations and diagnostic kits which comprise a monoclonal antibody as derived above.
  • Monoclonal antibodies of the present invention are produced by preparing hybridoma cell lines capable of producing desired antibodies, and culturing the cell lines to obtain the monoclonal antibodies.
  • the cell lines of the present invention are prepared by; (1) preparing antibody-producing cells by immunizing an animal with cells of human cancer origin, (2) fusing the antibody-producing cells with tumor cells to obtain hybridomas capable of producing the monoclonal antibody and immortalized, and (3) cloning and selecting hybridoma producing the desired monoclonal antibody.
  • the desired monoclonal antibody is produced by; (4) culturing the hybridoma in vitro in a culture medium, or in vivo in an animal, and (5) recovering the monoclonal antibody from the cultured medium, or from ascites obtained from the animal.
  • Antibody-producing cells may be prepared according to any known process as described, for example, in Methods in Enzymology , 73 , 14 (1981), by immunizing animals with cells of human cancer origin, removing the spleens from the animals, and preparing splenocyte suspension from the spleens.
  • antibody-producing cells can be prepared by obtaining splenocytes from not-immunized animals, and immunizing the splenocytes in vitro with cells of human cancer origin.
  • mice are immunized intraperitoneally with TMK-l cells and boosted twice every ten days, and after the last boost, the spleens are removed from the immunized mice and antibody-producing cells are prepared from the spleens.
  • the TMK-l cell line is a tissue culture cell line of SC-6-JCK cells which are transplanted into nude mice from human poorly-differentiated stomach adenocarcinoma cells (see Gan no Rinsho , 27 , 1605-1612, 1981, Japan).
  • the antibody-producing cells prepared as above are fused with tumor cells in the presence of a fusion agent to form a hybridoma which produces monoclonal antibodies and which is immortalized.
  • the general fusion procedure is well known and described, for example, in J. Immunol. Methods , supra; and Nature , supra.
  • the above-described antibody-producing cells are fused with tumor cells P3-X63-Ag8U1 (P3Ul) ( Methods in Enzymol. , 73 , 3-46, 1981) in RPMI-1640 medium in the presence of 40% polyethylene glycol.
  • HAT medium i.e., RPMI-1640 medium supplemented with hypoxanthine, aminopterin, and thymidine
  • Hybridoma can grow in the HAT medium, but parent cells cannot grow.
  • Supernatants in which hybridoma have been grown are arrayed to detect the presence of the desired monoclonal antibody.
  • the assays are carried out by, for example, the plaque method, agglutination method, radioimmunoassay method, and conveniently, the ELISA method ( Methods in Enzymol. , 70 , 419-439, 1980).
  • Hybridoma prepared as above is cultured in a culture medium such as an RPMI-1640 medium supplemented with 10 to 20% of fetal bovine serum ( Methods in Enzymol. , 73 , 42-43, 1981), or is injected intraperitoneally into an experimental animal such as a rat or mouse in which the hybridoma cells can be grown to culture the cells in vivo ( Methods in Enzymol. , 73 , 43-44, 1981), to produce the monoclonal antibody in the cultured medium or ascites from the animal.
  • the monoclonal antibody produced is recovered from the cultured medium or the ascites according to any conventional method, such as ammonium sulfate precipitation, and purified, for example, by gel filtration, ion exchange chromatography, or affinity column chromatography, or a combination thereof (see, Monoclonal Antibodies , 405, 1980, Plenum Press).
  • the specificity of the monoclonal antibodies prepared according to the present invention is determined by ELISA using cancer cells immobilized on a support. Alternatively, the determination can be carried out by a commercially available kit using tissue preparations of cancer cells.
  • the ABC method J. Histochem. Cytochem. , 29 , 577, 1981
  • T.M. Vectastain
  • the present monoclonal antibodies react with various kinds of histological typing of stomach cancer regardless of the extent of differentiation. Such a property is also especially remarkable in monoclonal antibodies produced by hybridoma 9A3 and 20Dll.
  • the present monoclonal antibodies react with cancer cells from other organs including cells of lung cancer, breast cancer, cancer of the tongue, cancer of the esophagus, duodenal cancer, bile duct cancer, carcinoma of skin, colon cancer, and salivary grand cancer, etc.
  • mice were immunized by intraperitoneal injection of 106 cells of poorly-differentiated human stomach adenocarcinoma cell line TMK-l, and were boosted twice every ten days after the first immunization. Three days after the last boost, spleens were removed from the immunized mice, and were teased to suspend splenocytes in an RPMI-1640 medium, which splenocytes were then filtered through a nylon mesh filter to prepare a mouse splenocyte suspension at a concentration of 2 x 106 cells/ml.
  • a suspension of mouse tumor cells P3Ul (Flow) in RPMI-1640 medium was prepared according to a conventional method.
  • the cell pellet on the bottom of the test tube was gradually added dropwise with 1 ml of PSB(-) (8.0 g sodium chloride, 0.2 g monopotassium dihydrogen phosphate anhydride, 1.5 g disodium hydrogen phosphate anhydride, 0.2 g potassium chloride in 1000 ml water) containing 40% of polyethylene glycol (PEG) having a molecular weight of 4000.
  • PSB(-) 8.0 g sodium chloride, 0.2 g monopotassium dihydrogen phosphate anhydride, 1.5 g disodium hydrogen phosphate anhydride, 0.2 g potassium chloride in 1000 ml water
  • PEG polyethylene glycol
  • the diluted mixture was then centrifuged to remove a supernatant, the remaining cells were diluted with an RPMI-1640 medium supplemented with 10% FCS to a concentration of 1.0 x 105 cells/ml, and 100 ⁇ l of the suspension was distributed to each well of a 96-well plate, which well has been previously added with 100 ⁇ l of a suspension containing 5 x 105 of thymus cells derived from a three-week old Balb/c mouse as feeder cells.
  • the above-mentioned HAT medium is an RPMI-1640 medium supplemented with 100 ⁇ M hypoxanthine, 0.1 ⁇ M aminopterin, 1.6 ⁇ M thymidine, 10% FCS, 5 x 10 ⁇ 5 M 2-mercaptoethanol, 2 mM glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin (pH 7.4).
  • TMK-l cells were suspended in a Tris-HCl buffer (pH 7.4) containing 0.25 M sucrose, the suspension was homogenized, and the homogenate was centrifuged to remove a supernatant. The precipitate was resuspended in the same buffer, and the suspension was centrifuged to remove a supernatant. The precipitate was resuspended in PBS to obtain a cell suspension at a concentration of 2 x 106 cells/ml.
  • the PBS was PBS(-) supplemented with 1.0 g/l calcium chloride and 1.0 g/l magnesium chloride.
  • PBS(-) supplemented with 10 ⁇ g/ml poly-L-lysine were distributed to each well of a 96-well plate (Falcon), the plate was allowed to stand for 30 minutes at a room temperature, and was then washed with PBS(-)-Tween (supplied by Wako).
  • the PBS(-)-Tween is (PBS)(-) supplemented with 0.5 ml/l Tween 20.
  • Each of the wells was then added with 50 ⁇ l of PBS(-) supplemented with 0.5% glutaraldehyde, incubated for 15 minutes at a room temperature, and washed twice with TBS(-)-Tween.
  • Each of the wells was then added with 50 ⁇ l of PBS(-) supplemented with 1% bovine serum albumin (BSA) and 100 mM glycine, incubated for 30 minutes at a room temperature, and washed once with PBS(-)-Tween.
  • BSA bovine serum albumin
  • Each of the wells was then added with 250 ⁇ l of PBS(-) supplemented with 1% BSA, incubated for two hours at a room temperature, and washed with PBS(-)-Tween.
  • a control plate was prepared by using normal stomach mucous membranes cells instead of TMK-l cells, under the same procedure as above.
  • a supernatant was sampled from the wells in which a colony was formed, and 50 ⁇ l of the sample was added to a well of each of two plates prepared as above. The plates were incubated for two hours, and washed three times with PBS(-)-Tween. 50 ⁇ l of a peroxidase-labeled goat anti-mouse immunoglobulin (Kirkegaard and Perry Lab) was added to each well, and the plates were incubated for two hours at a temperature of 37°C in the presence of 5% carbon dioxide. After four times of washing with PBS(-)-Tween, each well was added with 100 ⁇ l of a substrate solution for an assay of enzyme activity fixed to the plate.
  • the substrate solution was 0.1 M of a citrate buffer containing 2.5 mM 2,2'-azinobis(3-ethylbenzothiazoline)-6-sulphonic acid (ABTS) and 5 mM hydrogen peroxide, and was prepared immediately before use.
  • ABTS 2,2'-azinobis(3-ethylbenzothiazoline)-6-sulphonic acid
  • the enzyme reaction was carried out for 5 to 15 minutes and terminated by the addition of 100 ⁇ l/well of 2 mM sodium azide, and absorption at 405 mm (OD405) was measured with a Titertek Multiscan (T.M.) (Flow).
  • Each of ten hybridoma obtained as above was cultured in 100 ml of an RPMI-1640 medium supplemented with 10% FCS at a temperature of 37°C in the presence of 5% carbon dioxide in a carbon dioxide incubator for 4 days. After the culturing, monoclonal antibodies were recovered from the supernatants by ammonium sulfate precipitation. The recovered monoclonal antibodies were characterized as shown in Table 1.
  • Stomach cancer tissue sections obtained from human patients were incubated in methanol containing 0.3% hydrogen peroxide to block peroxidase activity present in the tissue.
  • the tissue sections were then washed with PBS(-), incubated with normal horse serum diluted 20 times with PBS(-), and washed with PBS (-).
  • the sections were then incubated with biotinated horse anti-mouse immunoglobulin (Vector) at a room temperature for 60 minutes, and then washed with PBS(-).
  • the sections were then incubated with avidin and biotinated peroxidase conjugate for 60 minutes at a room temperature, and washed with PBS(-).
  • (med) represents medullary carcinoma
  • (sci) represents scirrhous carcinoma.
  • the symbols +, ⁇ , and - have the following meanings:
  • monoclonal antibodies according to the present invention react with human cancer cells but do not react with normal cells. Therefore, the monoclonal antibodies can be used for the diagnosis of cancer.
  • a monoclonal antibody conjugated with label material such as an enzyme, fluororescent material, etc.
  • label material such as an enzyme, fluororescent material, etc.
  • a monoclonal antibody conjugated with metal protein such as ferritin, which produces an electron interference, is reacted with a sample.
  • metal protein such as ferritin
  • monoclonal antibodies of the present invention react with cancer cells from more than one human organ, one monoclonal antibody can be used to diagnose cancer from more than one organs. Moreover, as monoclonal antibodies of the present invention react with cancers having various differentiation extents, including poorly-differentiation, these antibodies can be used for the diagnoses of cancer having from a poorly-differentiation to a well-differentiation.
  • Monoclonal antibodies produced by hybridomas 9A3, and 20Dll notably show the above-mentioned characteristics. As these antibodies react relatively strongly with stomach cancer cells but substantially do not react with normal cells except for neutrophil leucocyte and macrophage, they are especially useful for the diagnosis of stomach cancer.
  • monoclonal antibodies of the present invention in combination with a chemotherapeutic agent for cancer therapy, may be used for a so-called missile therapy wherein the monoclonal antibody selectively directs the agent to the cancer cells ( British Medical Journal ), 285 , 461-462, 1982; and 285 , 1447, 1982).
  • the preferable hybridoma cell lines of the present invention are 9A3, which was designated as SCI 9A3, and 20Dll, which was designated as SCI 20Dll which were deposited to Institute of Fermentation, Osaka (IFO), 17-85 Juso-honmachi 2-chome Yodogawa-ku, Osaka, Japan, on October 18, 1985, as IFO-50061 and IFO-50062 respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (5)

  1. Lignée cellulaire d'hybridome capable de produire un anticorps monoclonal contre le cancer humain, lequel hybridome est choisi parmi l'IFO-50061 et l'IFO-50062.
  2. Anticorps monoclonal contre le cancer humain qui est produit par une lignée cellulaire d'hybridome selon la revendication 1.
  3. Procédé de production d'un anticorps selon la revendication 2, qui comprend la culture de cet hybridome dans un milieu de culture in vitro, ou dans l'organisme d'un animal dans lequel les cellules d'hybridome peuvent se développer, et la récupération de l'anticorps monoclonal dans le milieu de culture ou dans des ascites prélevés chez cet animal, et une purification optimale de cet anticorps par un procédé classique.
  4. Préparation pharmaceutique pour le traitement du cancer humain, qui comprend un anticorps monoclonal selon la revendication 2, ainsi qu'un ou plusieurs excipients.
  5. Kit de diagnostic pour le diagnostic du cancer humain, qui comprend un anticorps monoclonal selon la revendication 2, ainsi qu'un ou plusieurs réactifs de dosage.
EP85307678A 1984-10-26 1985-10-24 Anticorps monoclonal contre le cancer humain Expired EP0180413B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP22383084A JPS61103837A (ja) 1984-10-26 1984-10-26 抗ヒト癌モノクロ−ナル抗体
JP223830/84 1984-10-26
JP198592/85 1985-09-10
JP60198592A JPS61104783A (ja) 1985-09-10 1985-09-10 抗ヒト癌モノクロ−ナル抗体生産性ハイブリド−マ

Publications (3)

Publication Number Publication Date
EP0180413A2 EP0180413A2 (fr) 1986-05-07
EP0180413A3 EP0180413A3 (en) 1988-11-30
EP0180413B1 true EP0180413B1 (fr) 1991-10-02

Family

ID=26511069

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85307678A Expired EP0180413B1 (fr) 1984-10-26 1985-10-24 Anticorps monoclonal contre le cancer humain

Country Status (3)

Country Link
US (1) US5021553A (fr)
EP (1) EP0180413B1 (fr)
DE (1) DE3584280D1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0218158A3 (fr) * 1985-09-30 1988-12-07 Asahi Kasei Kogyo Kabushiki Kaisha Anticorps monoclonal humain, lignée de cellules B pour la production de cet anticorps et méthode de préparation de cette lignée de cellules B et de cet anticorps.
JPS62207298A (ja) * 1986-03-06 1987-09-11 Kyowa Hakko Kogyo Co Ltd 抗ヒト胃癌単クロ−ン性抗体
JPH0673470B2 (ja) * 1986-07-15 1994-09-21 協和醗酵工業株式会社 抗ヒト胃癌単クロ−ン性抗体ａｍｃ−４６２
US5013645A (en) * 1987-04-14 1991-05-07 Abbott Laboratories Immunological methods and materials for detection of tumor associated antigens
US5118611A (en) * 1988-07-25 1992-06-02 Adeza Biomedical Corporation Adenocarcinoma antigen binding methods and reagents
GB2393729A (en) * 2002-10-04 2004-04-07 Nanomagnetics Ltd Semiconductor nanoparticles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4569788A (en) * 1983-05-18 1986-02-11 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies against non small cell lung cancer
DE3531301A1 (de) * 1985-09-02 1987-03-05 Behringwerke Ag Monoklonale antikoerper gegen tumorassoziierte glykoproteine, verfahren zu ihrer herstellung sowie ihre verwendung
DE3416774A1 (de) * 1984-05-07 1985-11-14 Behringwerke Ag, 3550 Marburg Monoklonale antikoerper, verfahren zu ihrer herstellung sowie ihre verwendung
US4683200A (en) * 1984-05-17 1987-07-28 Setsuo Hirohashi Monoclonal antibody to human cancer antigen and method for producing same

Also Published As

Publication number Publication date
US5021553A (en) 1991-06-04
EP0180413A2 (fr) 1986-05-07
DE3584280D1 (de) 1991-11-07
EP0180413A3 (en) 1988-11-30

Similar Documents

Publication Publication Date Title
US4683200A (en) Monoclonal antibody to human cancer antigen and method for producing same
JP2546570B2 (ja) ヒト乳癌細胞に対するモノクローナル抗体を生産するハイブリドーマ
KR100246681B1 (ko) 종양, 탄수화물 항원에 특이한 모노클로날 항체 및 세포계
BE1000611A5 (fr) Anticorps monoclonaux et antigene du carcinome pulmonaire humain a cellules non petites et de certains autres carcinomes humains.
EP0180413B1 (fr) Anticorps monoclonal contre le cancer humain
EP0184369B1 (fr) Anticorps monoclonal spécifique de l'antigène de surface cellulaire de tumeur mammaire
US4855235A (en) Monoclonal antibodies to human leukocyte antigens
CA1238285A (fr) Anticorps monoclonal specifique contre un antigene cytoplasmique de cellules de tumeurs mammaires
JP3594318B2 (ja) 抗ヒトスカベンジャーレセプター抗体
US5032521A (en) Monoclonal antibody specific for a mammary tumor cell surface antigen
JPH0673470B2 (ja) 抗ヒト胃癌単クロ−ン性抗体ａｍｃ−４６２
JP3581160B2 (ja) 抗粘液糖タンパク質モノクローナル抗体
JPS61104783A (ja) 抗ヒト癌モノクロ−ナル抗体生産性ハイブリド−マ
US5352584A (en) Monoclonal antibodies which bind (E)-5- (2-bromovinyl)-arabinofuranosyluracil and diagnostic methods based thereon
JP2845568B2 (ja) モノクローナル抗体
KR0140365B1 (ko) 콜레스테롤 에스터라제를 특이적으로 인지하는 단세포군 항체와 이를 분비하는 융합세포주
JPS61236798A (ja) モノクロ−ナル抗体
JPS61103837A (ja) 抗ヒト癌モノクロ−ナル抗体
JP2000312595A (ja) 抗ヒトスカベンジャーレセプター抗体
JPH08208698A (ja) モノクローナル抗体
JPH0217160B2 (fr)
JPH06102038B2 (ja) モノクロ−ナル抗体
JPS6319562A (ja) 抗ラフオ−ラ小体単クロ−ン性抗体
JP2002519020A (ja) 腫瘍抗原ｕｋ１１４に対するヒトモノクローナル抗体並びにそれらの産生のためのリンパ性細胞及びハイブリドーマ
JPS60231622A (ja) ムチン性卵巣癌細胞モノクロ−ナル抗体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): DE FR GB

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): DE FR GB

17P Request for examination filed

Effective date: 19890222

17Q First examination report despatched

Effective date: 19900305

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE FR GB

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19911018

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19911025

Year of fee payment: 7

REF Corresponds to:

Ref document number: 3584280

Country of ref document: DE

Date of ref document: 19911107

ET Fr: translation filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19911129

Year of fee payment: 7

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19921024

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19921024

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19930630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19930701

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST